Quality has its own way of coming through

Coordinator: Prof. Dr Harald Schmidt, MD PhD PharmD, FESC, Maastricht University, The Netherlands
Funding scheme: Horizon Europe, 28 Partners
Duration: 84 months
Start: 01.09.2022
Objective: RePo4EU - A global innovative platform for repurposing already approved medicines. This reduces the time and cost of developing new therapies. Through systems medicine and AI, causal disease definitions are used, allowing more precise diagnoses. Patients participate to achieve the goals most relevant to them and thus make and shape their own decisions for their health.
Services of concentris: Coordination of the application, contract negotiations & project management
Website:  https://repo4.eu/

Coordinator: Dr. Véronique Dudouet
Funding scheme: Horizon Europe, 14 partners
Duration: 36 months
Start:  01.10.2022
Objective: EMBRACE analyses blockages to democratisation in the European neighbourhood, identifies ways to overcome them and suggests new policy tools for EU democracy promotion (EUDP). The aim is to take stock and assess the developments, instruments, ambitions and concepts of EU democracy promotion. Using a combined quantitative and qualitative research strategy, EMBRACE will develop an innovative policy toolkit to further develop existing EUDP instruments and identify new approaches for the EU. In this way, the research project aims to foster partnerships for a more stable and secure European neighbourhood and to create incentives for political actors to embrace democratic change.
Services of concentris: Coordination of the application, contract negotiations, project management
Website:  https://embrace-democracy.eu/

Coordinator: Prof Neeltje van Haren, Erasmus MC
Funding scheme: Horizon Europe, 18 partners
Duration: 60 months
Start: 01.10.2022
Objective: The FAMILY consortium aims to improve the lives of mentally ill people with novel predictive models. In-depth causal analysis (how and when the risk of mental illness occurs) helps to identify risk and resilience factors early and in a family-based way, and to predict who may develop mental symptoms – serving as new targets for the development of prevention strategies. Leistung von concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://family-project.eu

Coordinator: Prof. Dr. med. Klaus Pantel, University Medical Center Hamburg-Eppendorf, Germany
Funding scheme: Horizon Europe, 17 partners
Duration: 60 months
Start: 01.01.2023
Objective: As pancreatic cancer is usually detected at late stages and as most patients die within one year after diagnosis, the main objective of the PANCAID consortium is to develop and provide a minimally invasive blood test the for early detection of pancreatic cancer and the malignant conversion of premalignant to invasive lesions.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://www.pancaid-project.eu/

Coordinator: Prof. Dr. Henrik Larsson (ORU)
Funding scheme: Horizon2020, 17 partners
Duration: 60 month
Start: 01.04.2021
Objective: Emerging evidence points at a significant association and shared genetic traits between adult attention-deficit/hyperactivity disorder (ADHD) and cardiometabolic conditions such as obesity, type 2 diabetes, and cardiovascular disease, which, when inadequately treated, can lead to adverse outcomes and significant costs for society. This is where TIMESPAN steps in, fostering improvements in risk stratification and improvement of the treatments already available for patients with ADHD who also have a cardiometabolic disease.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://timespan.eu/

Coordinator: Prof. Dr. Rajiv Jalan (EFCLIF)
Funding scheme: Horizon2020, 14 partners
Duration: 60 months
Start: 01.03.2021
Objective: In its final stages, decompensated cirrhosis leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy for ACLF that repurposes an antagonist (TAK-242) of Toll-like receptor 4 (TLR4) in combination with granulocyte colony-stimulating factor (G-CSF). This novel combinatorial therapy is called “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://a-tango.eu/

Coordinator: Univ.-Prof. Dr. med. Jörg Faber (UMC-Mainz)
Funding scheme: Horizon2020, 16 partners
Duration: 66 months
Start: 01.03.2021
Objective: FORTEe promotes exercise oncology that aims at making patients stronger to fight childhood cancer. Supervised exercise training intends to increase muscle strength and reduce muscular atrophy due to bed rest. Within the project, digital, innovative technologies such as augmented reality will be developed and applied to make the exercise training more effective, age-adapted and personalised. FORTEe has the ambition to implement paediatric exercise oncology as an evidence-based standard in clinical care for all childhood cancer patients across the EU and beyond.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://fortee-project.eu/

Coordinator: Prof. Dr. Pierre-Emmanuel Ratou (APHP, EFCLIF, INSERM)
Funding scheme: Horizon2020, 21 partners
Duration: 66 months
Start: 01.04.2020
Objective: DECISION's objective is to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) or death. The project's research consortium takes advantage of many already existing biosamples and clinically well-characterized patient cohorts to develop prognostic and response tests and combinatorial therapies tailored to the needs of individual patients. The primary goal is to significantly decrease the mortality rate for end-stage liver cirrhosis in Europe.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://decision-for-liver.eu/

Coordinator: Prof. Dr. Elizabeth CM de Lange (ULEI)
Funding scheme: Horizon2020, 10 partners
Duration: 60 months
Start: 01.01.2020
Objective: QSPainRelief aims to develop effective drug combination treatments for the improved relief of chronic pain. A quantitative systems pharmacology (QSP) mathematical modelling approach will be used to identify and validate more effective therapeutic interventions by smart combinations of existing drugs. The ultimate goal is to personalise and maximize pain relief for individuals suffering from chronic pain while diminishing side effects.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination management
Website:  https://www.qspainrelief.eu/

Coordinator: Prof. Dr. Barbara Franke (RUMC)
Funding scheme: Horizon2020, 17 partners
Duration: 60 months
Start: 01.01.2020
Objective: PRIME addresses insulin-related signalling as a novel, key-modulator of comorbid mental and non-mental diseases, and aims at generating innovative diagnostic and treatment strategies to improve the monitoring and clinical outcomes of patients. The project is aiming to increase the understanding of causal mechanisms underlying insulin-related multimorbidity and improving the management of insulin multimorbidity across the lifespan by developing intervention and preventative strategies.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://prime-study.eu/

Coordinator: Dr. Yann Herault (CERBM)
Funding scheme: Horizon2020, 12 participants
Duration: 66 months
Start: 01.01.2020
Objective: The overarching aim of GO-DS21 is to elucidate etiological mechanisms involved in the common morbidities of obesity and intellectual disability. GO-DS21 will explore how intrinsic (genetic and pathway-driven) and extrinsic (environmental and epigenetic) factors can lead to such comorbid states.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://www.go-ds21.eu/

Coordinator: Prof. Dr. Jonel Trebicka, European Foundation for the Study of Chronic Liver Failure (EF-Clif)
Funding scheme: Horizon2020, 22 participants
Duration: 75 months
Start: 01.01.2019
Objective: MICROB-PREDICT investigates the human microbiome to identify predictors and mechanisms associated with the development of decompensation of cirrhosis and progression to acute-on-chronic liver failure (ACLF) and death.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://www.microb-predict.eu/

Coordinator: Prof. Dr. Jan Baumbach, University of Hamburg (UHAM)
Funding scheme: Horizon2020, 9 participants
Duration: 60 months
Start: 01.01.2019
Objective: Revolutionizing cloud communication - FeatureCloud is a novel artificial intelligence platform, based on a ground-breaking new cloud infrastructure for medical data exchange – totally anonymous by default.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://www.featurecloud.eu/

Coordinator: Prof. Dr. Raffael Kalisch, Leibniz Institute for Resilience Research, Germany
Funding scheme: Horizon2020, 15 partners
Duration: 66 months
Start: 01.04.2018
Objective: The overall aim of DynaMORE is to improve the prevention of, or quick recovery from, stress-related mental health problems. We hope to increase individual well-being, reduce healthcare demands and indirect economic costs, and contribute to a healthier society. An in silico model of stress resilience will be used as a basis for developing a novel mobile health (mHealth) product to prevent stress-related disorders and to support individuals in an effective and personalised way.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://dynamore-project.eu/

Coordinator: Prof Dr Harald Schmidt, MD PhD PharmD, FESC, Universiteit Maastricht, The Netherlands
Funding scheme: Horizon2020, 9 partners
Duration: 66 months
Start: 01.02.2018
Objective: An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://repo-trial.eu/

Coordinator: Dr. Alejandro Arias Vasquez, Radboud University Nijmegen, The Netherlands
Funding scheme: Horizon2020, 18 partners
Duration: 66 months
Start: 01.09.2017
Objective: The project's goal is to identify nutrition and lifestyle drivers that can be employed to prevent detrimental impulsivity/compulsivity in humans across the lifespan. The project aims to characterize the etiologic paths leading to extreme behaviour and promote policy changes to counteract maladaptive impulsivity/compulsivity by disseminating evidence-based information about health-related behaviours to families, clinicians, policy makers and the general public.
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  http://eat2benice.eu/

Coordinator: Dr. Peter Roberts, University of Manchester, UK
Funding scheme: Horizon2020, 9 partners
Duration: 63 months
Start: 1.1.2017
Objective: Radical redesign of Earth observation platforms for sustained operation at significantly lower altitudes than the current state of the art, using a combination of new aerodynamic materials, aerodynamic control and airbreathing electric propulsion for drag-compensation, for a variety of observation methods with the aim of creating a new platform paradigm.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination
Website:  http://discoverer.space/

Coordinator:  Maaike Beltman, TNO innovation for life, Bergen op Zoom, NL
Funding scheme: Horizon2020, 20 partners
Duration: 57 months
Start: 1.1.2017
Objective: to improve the health, development and quality of life of children and adults born very preterm (VPT, < 32 weeks of gestation) or very low birth weight (VLBW, < 1500g) – approximately 50 000 births each year in Europe – by establishing an ICT platform to integrate, harmonise and exploit the wealth of data from 20 European cohorts of VPT/VLBW children and adults and their families constituted from the early 1980s to the present, together with data from national registries.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination
Website:  http://recap-preterm.eu/

Coordinator: Dr. Vincent Jaddoe, ErasmusMC, Rotterdam, NL
Funding scheme: Horizon2020, 18 partners
Duration: 66 months
Start: 1.1.2017
Objective: To bring together pregnancy and child cohort studies into a new, open and sustainable EuroCHILD Cohort Network, to use this network for identification of novel markers of early-life stressors affecting health trajectories throughout the lifecycle, and translate findings into policy recommendations for stratified and targeted prevention strategies.
Services of concentris: dissemination and website
Website:  http://lifecycle-project.eu/

Coordinator: Prof. Dr. Andreas Reif, Goethe University Frankfurt
Funding scheme: H2020, 17 partners
Duration: 66 months
Start: 1.1.2016
Objective: Understanding mechanisms underlying co-morbid disorders of Attention deficit / Hyperactivity Disorder (ADHD).
Services of concentris: coordination of the application, contract negotiations, project management, dissemination
Website:  http://www.coca-project.eu

Coordinator: Prof. Martin Gotthardt, Radboud University Medical Centre, The Netherlands
Funding scheme: FP7, Collaborative Project, 17 beneficiaries
Duration: 48 months
Start: 1.4.2014
Objective: Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. In order to significantly improve therapy of this disease, BetaCure aims at developing a simultaneous imaging/therapy platform allowing diagnostic imaging as well as image guided surgical, to selectively resect/destroy diseased beta cells.
Services of concentris: coordination of the application, contract negotiations, project management, Dissemination.

Coordinator: Dr. Jeffrey Glennon, Radboud University Nijmegen, The Netherlands
Funding scheme: FP7, Collaborative Project, 19 beneficiaries
Duration: 60 months
Start: 1.3.2014
Objective: To identify the neural, genetic and molecular factors involved in the pathogenesis of aggression/antisocial behaviour in (i) normally developing adolescents, (ii) children and adolescents with Attention-Deficit Hyperactivity Disorders (ADHD), and (iii) children and adolescents with Conduct Disorder (CD).
Services of concentris: coordination of the application, contract negotiations, project management, Dissemination.

Coordinator: Prof. Swaran Singh, Warwick Medical School, UK
Funding scheme: FP7, Collaborative Project, 12 beneficiaries
Duration: 60 months
Start: 1.2.2014
Objective: The overall objective of MILESTONE is to enhance the transition from the Child and Adolescent Mental Health (CAMHS) to Adult Mental Health (AMHS) Services across Europe. The MILESTONE project is an EU-wide study determining care gaps in current services across diverse healthcare systems, robustly evaluating an innovative transitional care model and to create clinical, organisational, policy and ethics guidelines for improving care and outcomes for transition age youth.
Services of concentris: coordination of the application, contract negotiations, project management, Dissemination.
Website:  http://www.milestone-transitionstudy.eu

Coordinator: Prof. Dr. Thomas Gress and PD Dr. Malte Buchholz, Philipps-University Marburg, Germany
Funding scheme: FP7, Collaborative Project, 11 beneficiaries
Duration: 60 months
Start: 1.11.2013
Objective: The overall aim of CAM-PaC is to use a strongly SME-driven approach to contribute to solving the socioeconomic and health challenges of PDAC by an integrative and systematic functional analysis of pancreatic cancer candidate genes. CAM-PaC will develop novel cellular and animal models, as well as novel strategies to analyse and integrate large scale metabolic, transcriptomic and genetic data from these models, in order to systematically identify, characterise and validate novel targets for therapeutic intervention and bioinfomatic models for predictive diagnostics.
Services of concentris: coordination of the application, contract negotiations, project management, Dissemination.

Coordinator: Prof. Barbara Franke, Radboud University Nijmegen Medical Centre, The Netherlands
Funding scheme: FP7, Collaborative Project, 23 beneficiaries
Duration: 60 months
Start: 1.11.2013
Objective: To gain a deeper understanding of different types of aggression in patients with ADHD, conduct disorder, as well as in the general population in order to better predict aggression development. In addition to the diagnostic-preventive approach, pharmacological as well as non-pharmacological means of personalized treatment will be tested.
Services of concentris: coordination of the application, contract negotiations, project management, Dissemination.
Website:  http://www.aggressotype.eu

Coordinator: Prof. Dr. Andreas Meyer-Lindenberg, Zentralinstitut für Seelische Gesundheit, Mannheim, Germany
Funding scheme: FP7, Collaborative Project, 14 beneficiaries
Duration: 48 months
Start: 1.10.2013
Objective: To improve the clinical management and aetiological understanding of mental illness through discovery of neuroimaging based diagnostic, trans-diagnostic and predictive markers and their translation into clinical tests and therapeutics.
Services of concentris: coordination of the application, contract negotiations, project management, Dissemination.
Website:  http://www.imagemend.eu

Coordinator: Prof. Baziel van Engelen, Radboud University Nijmegen Medical Centre, The Netherlands
Funding scheme: FP7, Collaborative Project, 8 beneficiaries
Duration: 48 months
Start: 1.11.2012
Objective: To improve clinical practice in the management of patients with Myotonic dystrophy type 1 for which no dedicated treatment is currently available.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination.

Coordinator: Prof. Dr. Jan Buitelaar, Dr. Jeffrey Glennon, Radboud University Nijmegen, The Netherlands
Funding scheme: FP7, Collaborative project, 11 beneficiaries
Duration: 60 months
Start: 1.2.2012
Objective: Compulsivity: A series of ‘proof-of-concept’ studies, the cohesion of structural neuroimaging studies, neurochemistry, behavior, genetics, proteomics and machine learning tools in paediatric clinical populations and behavioral animal models will seek to better understand underlying mechanisms related to glutamate dysfunction in frontostriatal circuits and its remediation / prevention by early intervention studies with glutamate-based clinically used drugs.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination.

Coordinator: Dr. Pieter Hoekstra, Academisch Ziekenhuis Groningen, The Netherlands
Funding scheme: FP7, Collaborative project, 27 beneficiaries
Duration: 66 months
Start: 1.12.2011
Objective: EMTICS will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination, training organization

Coordinator: Prof. David Collier, King`s College London (Institute of Psychiatry), UK
Funding scheme: FP7, SME-targeted collaborative project, 9 beneficiaries
Duration: 48 months
Start: 1.11.2011
Objective: CRESTAR is an SME-driven project focusing on the development of pharmacogenomic biomarkers for schizophrenia. It aims to develop tools to predict which patients will not respond to usual antipsychotics, and the 1% of patients who will develop potentially fatal side effects which is the main factor limiting clozapine use, and diabetic ketoacidosis, occurring in up to 2% of patients.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination.

Coordinator: Prof. Dr. Thomas Gress, Philipps-Universität Marburg
Funding scheme: FP7, Collaborative project, 15 beneficiaries
Duration: 36 months
Start: 1.2.2011
Objective: The overall objective of this project is to improve survival of pancreatic cancer patients by exploring the contribution of the tumour microenvironment to the failure of presently available oncological treatments.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination

Coordinator: Dr. Paramala Santosh, King’s College London, Maudsley Hospital, London, UK
Funding scheme: FP7, Collaborative project, 16 beneficiaries
Duration: 54 months
Start: 1.11.2010
Objective: The STOP project aims to develop a comprehensive web-based methodology for the assessment and monitoring of suicidality in children and adolescents.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination, training organization
Website:  http://www.stop-study.com

Coordinator: Prof. Dr. Thomas Gress, Philipps-Universität Marburg, Germany
Funding scheme: FP6, Integrated Project, 21 participants
Duration: 42 months
Objective: The overall aim of this project is to make use of genetic profiles of pancreatic cancer and precursor lesions to improve the outcome of pancreatic cancer patients by providing novel and highly efficient molecular diagnostic tools.
Services of concentris: Third periodic and final reporting

Coordinator: Prof. Dr. Dr. h.c. Hans A. Kretzschmar, Ludwig-Maximilians-University Munich, Germany
Funding scheme: FP6, Network of Excellence, 19 participants
Duration: 66 months
Objective: BrainNet Europe is a consortium of 20 brain banks seeking to spread excellence in collecting human high quality post mortem brain tissue and to foster research in the cellular and molecular basis of neurological and mental disorders and diseases, gender aspects and the ageing process.
Services of concentris: Project management, dissemination, training organization.
Website:  http://www.brainnet-europe.org

Coordinator: Prof. Dr. Martien Kas, University of Groningen, The Netherlands
Project leader: Dr. Hugh Marston, Boehringer Ingelheim, Germany
Funding scheme: IMI2, Collaborative project, 14 partners
Duration: 36 months
Start: 01.06.2021
Objective: The overall aim of PRISM 2 is to accelerate the development of effective treatments for patients suffering from neuropsychiatric disorders by implementing a quantitative, transdiagnostic neurobiological approach. The focus lies on researching the relationship between default mode network (DMN) integrity and social dysfunction in schizophrenia (SZ) and Alzheimer’s Disease (AD), and Major Depressive Disorder (MDD).
Services of concentris: Coordination of the application, contract negotiations, project management, dissemination
Website:  https://prism2-project.eu/

Coordinator: Prof. Malcolm Macleod, The University of Edinburgh, United Kingdom
Project leader: Dr. Thomas Steckler, Janssen Pharmaceutica NV, Belgium
Funding scheme: IMI2, 29 partners
Duration: 48 months
Start: 01.10.2017
Objective: The project's aim is to enable a smoother, faster and safer transition from preclinical to clinical testing and drug approval by establishing common guidelines to strengthen the robustness, rigor and validity of research data.
Services of concentris: Project management & Dissemination
Website:  http://www.eqipd.org

Coordinator: Prof. Dr. Martien Kas, University of Groningen, The Netherlands
Managing Entity: Dr. Hugh Marston, Eli Lilly and Company Ltd
Funding scheme: IMI 2, Collaborative project, 23 partners
Duration: 36 months
Start: 1.4.2016
Objective: The PRISM project aims to unpick the biological reasons underlying social withdrawal, which is a common early symptom of, Schizophrenia, Alzheimer’s disease and Major Depressive Disorder, and thereby addresses the lack of understanding of the root biological causes which is one of the reasons behind the dramatic slowdown in the development of new drugs to treat neuropsychiatric disorders.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination.
Website:  http://www.prism-project.eu

Coordinator: Bart Vannieuwenhuyse, Janssen Pharmaceutica, Belgium
Managing Entity: Prof. Johan van der Lei, Erasmus Universitair Medisch Centrum Rotterdam
Funding scheme: IMI, Collaborative project, 57 partners
Duration: 60 months
Start: 1.1.2013
Objective: EMIF aims to develop a sustainable and scalable information framework which has the potential to access medical data on a scale and at a level of detail not currently available, thus opening avenues of research that so far have been out of reach. Two research questions – the identification of predictors and diagnostic biomarkers for Alzheimer’s Disease as well as for metabolic complications in adults and peadiatrics – will provide focus and guidance for the framework development.
Services of concentris: coordination of the application, contract negotiations, project management
Website:  http://www.emif.eu

Coordinator: Martin Graf, F. Hoffmann-La Roche
Managing Entity: Dr. Zameel Cader, University of Oxford
Funding scheme: IMI, Collaborative project, 35 partners
Duration: 60 months
Start: 1.10.2012
Objective: The aim of the STEMBANCC project is to generate and characterise 1,500 high quality human induced pluripotent stem (iPS) cell lines that can be used by researchers to study a range of diseases, including diabetes and dementia, and test for drug efficacy and safety. The cell lines will help to improve and speed up the drug development process, and ensure that patients benefit from more effective and safer drugs.
Services of concentris: coordination of the application, contract negotiations, project management, dissemination.

Coordinator: Prof. Jens Siveke
Funding scheme: BMBF, 17 partners
Duration: 60 months
Start: 01.07.2022
Objective: Tumours with marked tumour heterogeneity include triple-negative or luminal-B breast carcinoma (certain forms of breast cancer), as well as microsatellite-stable colorectal carcinoma (a subtype of colorectal cancer) and pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer). Among other things, the tumour heterogeneity makes these forms of cancer difficult to treat. In order to develop better treatment options here, a better understanding of the underlying mechanisms is needed. These are now being closely examined scientifically in the SATURN³ project.
Services of concentris: Coordination of the application, contract negotiations, project management
Website:  https://saturn3.org/